These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 8252489)
1. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Horibe K; Matsushita T; Numata S; Miyajima Y; Katayama I; Kitabayashi T; Yanai M; Sekiguchi N; Egi S Cancer; 1993 Dec; 72(12):3723-6. PubMed ID: 8252489 [TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukaemia in a patient treated with etoposide for Langerhans cell histiocytosis. Matsuzaki A; Inamitsu T; Watanabe T; Ohga S; Ishii E; Nagotoshi Y; Tasaka H; Suda M; Ueda K Br J Haematol; 1994 Apr; 86(4):887-9. PubMed ID: 7918090 [TBL] [Abstract][Full Text] [Related]
3. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans' cell histiocytosis. López-Andreu JA; Ferris J; Verdeguer A; Esquembre C; Castel V Cancer; 1994 Sep; 74(5):1650-2. PubMed ID: 7864932 [No Abstract] [Full Text] [Related]
4. Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Egeler RM Cancer; 1995 Jan; 75(1):134-6. PubMed ID: 7804969 [No Abstract] [Full Text] [Related]
5. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations. Haupt R; Fears TR; Heise A; Gadner H; Loiacono G; De Terlizzi M; Tucker MA Int J Cancer; 1997 Mar; 71(1):9-13. PubMed ID: 9096658 [TBL] [Abstract][Full Text] [Related]
6. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH). Lopes LF; de Camargo B Med Pediatr Oncol; 1999 Apr; 32(4):315. PubMed ID: 10102032 [No Abstract] [Full Text] [Related]
7. Langerhans cell histiocytosis and acute leukemia: unusual association in two cases. Aricò M; Comelli A; Bossi G; Raiteri E; Piombo M; Egeler RM Med Pediatr Oncol; 1993; 21(4):271-3. PubMed ID: 8469222 [TBL] [Abstract][Full Text] [Related]
8. [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone]. Mochiduki Y; Muramoto S Rinsho Ketsueki; 2005 Nov; 46(11):1218-22. PubMed ID: 16440807 [TBL] [Abstract][Full Text] [Related]
10. Acute leukemia in association with Langerhans cell histiocytosis. Egeler RM; Neglia JP; Aricò M; Favara BE; Heitger A; Nesbit ME Med Pediatr Oncol; 1994; 23(2):81-5. PubMed ID: 8202046 [TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the t(15;17) translocation in de novo and secondary acute promyelocytic leukemia. Naoe T; Kudo K; Yoshida H; Horibe K; Ohno R Leukemia; 1997 Apr; 11 Suppl 3():287-8. PubMed ID: 9209367 [TBL] [Abstract][Full Text] [Related]
12. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Ladisch S; Gadner H; Aricò M; Broadbent V; Grois N; Jacobson A; Komp D; Nicholson HS Med Pediatr Oncol; 1994; 23(2):107-10. PubMed ID: 8202031 [TBL] [Abstract][Full Text] [Related]
13. Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin's lymphoma in a child. Ogami A; Morimoto A; Hibi S; Todo S; Sugimoto T; Mori K; Imamura T; Ishida H; Yoshihara T; Iguchi A; Imaizumi M; Imashuku S J Pediatr Hematol Oncol; 2004 Jul; 26(7):427-30. PubMed ID: 15218416 [TBL] [Abstract][Full Text] [Related]
14. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation]. Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704 [TBL] [Abstract][Full Text] [Related]
15. Translocation (11;11)(p13- p15;q23) in a child with therapy-related acute myeloid leukemia following chemotherapy with DNA-topoisomerase II inhibitors for Langerhans cell histiocytosis. Silva ML; Land MG; Maradei S; Otero L; Veith M; Brito G; Klumb C; Fernandez T; Pombo-de-Oliveira MS Cancer Genet Cytogenet; 2002 May; 135(1):101-2. PubMed ID: 12072208 [TBL] [Abstract][Full Text] [Related]
16. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis. Haupt R; Fears TR; Rosso P; Colella R; Loiacono G; de Terlizzi M; Mancini A; Comelli A; Indolfi P; Donfrancesco A Pediatr Hematol Oncol; 1994; 11(5):499-507. PubMed ID: 7826846 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India. Narula G; Pradhan ND; Arora B; Banavali SD Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864 [TBL] [Abstract][Full Text] [Related]
18. Etoposide in Langerhans cell histiocytosis in children: a preliminary experience. Basade MM; Nair CN; Kurkure PA; Pai SK; Advani SH Pediatr Hematol Oncol; 1996; 13(2):159-62. PubMed ID: 8721030 [TBL] [Abstract][Full Text] [Related]
19. [Report of a case with secondary acute promyelocytic leukemia after therapy for hemophagocytic lymphohistiocytosis and review of literature]. Su Y; Zhou X; Zhang L; Zhang R Zhonghua Er Ke Za Zhi; 2013 Dec; 51(12):938-42. PubMed ID: 24495767 [TBL] [Abstract][Full Text] [Related]
20. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Minkov M Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]